References
- Furman R H. Are gonadal hormones (estrogens and androgens) of significance in the development of ischemic heart disease?. Ann NY Acad Sci 1968; 149: 822–33
- Heller R F., Jacobs H S. Coronary heart disease in relation to age, sex, and the menopause. Br Med J 1978; i: 472–74
- Stadel B V. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612–18
- Wilson P WF, Carrison R J., Castelli W P. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med 1985; 313: 1038–43
- Stampfer M J., Willett W C., Coldits G A., Rosner B, Speizer F E., Hennekens C H. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044–9
- Stamler J. The coronary drug project—findings with regard to estrogen dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977; 82: 52–75
- McDowell F, Louis S, McDevitt E. A clinical trial of premarin in cerebrovascular disease. J Chron Dis 1967; 20: 679–84
- Meade T W., Greenberg G, Thompson S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30/μg oestrogen preparations. Br Med J 1980; 280: 1157–61
- Kay C R. Progestogens and arterial disease. Evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 1982; 142: 762–65